Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877

Caveolin‐1 overexpression is associated with simultaneous abnormal expression of the E‐cadherin/α–β catenins complex and multiple erbb receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas

Masuelli, L., Budillon, A., Marzocchella, L., Mrozek, M., Vitolo, D., Gennaro, E. D., Losito, S., Sale, P., Longo, F., Ionna, F., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.24034 · Cited by 43

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation

Nurwidya, F., Takahashi, F., & Takahashi, K. (2016) · Journal of Natural Science Biology and Medicine · doi:10.4103/0976-9668.184695 · Cited by 43

Molecular differences in the microsatellite stable phenotype between left‐sided and right‐sided colorectal cancer

Takahashi, Y., Sugai, T., Habano, W., Ishida, K., Eizuka, M., Otsuka, K., Sasaki, A., Matsumoto, T., Morikawa, T., Unno, M., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30377 · Cited by 43

Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy

Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42

The inhibitory effects of 5‐hydroxy‐3,6,7,8,3′,4′‐hexamethoxyflavone on human colon cancer cells

Qiu, P., Guan, H., Dong, P., Guo, S., Zheng, J., Li, S., Chen, Y., Ho, C., Pan, M., McClements, D. J., et al. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100070 · Cited by 42

EGFR and c-Met cross talk in glioblastoma and its regulation by human cord blood stem cells

Velpula, K. K., Dasari, V. R., Asuthkar, S., Gorantla, B., & Tsung, A. J. (2012) · Translational Oncology · doi:10.1593/tlo.12235 · Cited by 42

HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF

Jeong, J. H., Kim, J., Hong, Y. S., Kim, D., Kim, J. E., Kim, S. Y., Kim, K., Yoon, Y., Kim, D., Chun, S., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.005 · Cited by 43

Novel molecular therapies in hepatocellular carcinoma

Faivre, S. J., Bouattour, M., & Raymond, É. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02395.x · Cited by 40

Cotargeting of Epidermal Growth Factor Receptor and PI3K Overcomes PI3K–Akt Oncogenic Dependence in Pancreatic Ductal Adenocarcinoma

Wong, M. H., Xue, A., Julovi, S. M., Pavlakis, N., Samra, J. S., Hugh, T. J., Gill, A. J., Peters, L., Baxter, R. C., & Smith, R. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3377 · Cited by 41

Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics

Katoh, M. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.128 · Cited by 44

An Activatable Nano‐Prodrug for Treating Tyrosine‐Kinase‐Inhibitor‐Resistant Non‐Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging

Xie, X., Zhan, C., Wang, J., Zeng, F., & Wu, S. (2020) · Small · doi:10.1002/smll.202003451 · Cited by 41

EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface

Adams, M. N., Harrington, B. S., He, Y., Davies, C. M., Wallace, S. J., Chetty, N., Crandon, A. J., Oliveira, N., Shannon, C., Coward, J. I. G., et al. (2014) · Oncogene · doi:10.1038/onc.2014.88 · Cited by 41

Topical Curcumin-Based Cream Is Equivalent to Dietary Curcumin in a Skin Cancer Model

Sonavane, K., Phillips, J. M., Ekshyyan, O. Y., Moore‐Medlin, T., Gill, J. R., Rong, X., Lakshmaiah, R. R., Abreo, F. W., Boudreaux, D., Clifford, J. L., et al. (2012) · Journal of Skin Cancer · doi:10.1155/2012/147863 · Cited by 40

Apoptosis Induced by Benzyl Isothiocyanate in Gefitinib-Resistant Lung Cancer Cells is Associated with Akt/MAPK Pathways and Generation of Reactive Oxygen Species

Liu, B., Yan, H., Wu, X., Pan, Z., Zhu, Y. T., Meng, Z., Zhou, Q., & Xu, K. (2012) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-012-9456-9 · Cited by 40

Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Lazzari, C., Spreafico, A., Bachi, A., Röder, H., Floriani, I., Garavaglia, D., Cattaneo, A., Grigorieva, J., Viganò, M. G., Sorlini, C., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307f17 · Cited by 40

An Unconventional KITENIN/ErbB4-Mediated Downstream Signal of EGF Upregulates c-Jun and the Invasiveness of Colorectal Cancer Cells

Bae, J. A., Yoon, S., Park, S. Y., Lee, J. H., Hwang, J., Kim, H., Seo, Y.-W., Cha, Y. J., Hong, S. P., Kim, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2863 · Cited by 41

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status

Formisano, L., D'Amato, V., Servetto, A., Brillante, S., Raimondo, L., Mauro, C. D., Marciano, R., Orsini, R. C., Cosconati, S., Randazzo, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4636 · Cited by 42

PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging

van Dijk, L. K., Boerman, O. C., Kaanders, J. H. A. M., & Bussink, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0348 · Cited by 40

Studies on the inhibition of feline EGFR in squamous cell carcinoma: Enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors

Bergkvist, G. T., Argyle, D. J., Pang, L. Y., Muirhead, R. H., & Yool, D. A. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.11.15525 · Cited by 40

Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity

Parmar, S., Schumann, C., Rüdiger, S., Boeck, S. H., Heinemann, V., Kächele, V., Seeringer, A., Paul, T., Seufferlein, T. T. W., & Stingl, J. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.51 · Cited by 40

Piroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitro

Rathore, K., Alexander, M. E., & Cekanova, M. (2014) · Translational research · doi:10.1016/j.trsl.2014.02.002 · Cited by 40

Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma

Uzawa, K., Amelio, A. L., Kasamatsu, A., Saito, T., Kita, A., Fukamachi, M., Sawai, Y., Toeda, Y., Eizuka, K., Hayashi, F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48717-w · Cited by 40

DNAJB1 negatively regulates MIG6 to promote epidermal growth factor receptor signaling

Park, S., Choi, H.-K., Seo, J. S., Yoo, J., Jeong, J., Choi, Y., Choi, K., & Yoon, H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.07.024 · Cited by 39

Thioamides in medicinal chemistry and as small molecule therapeutic agents

Huang, G., Cierpicki, T., & Grembecka, J. E. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116732 · Cited by 38

ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)

Prasetyanti, P. R., Capone, E., Barcaroli, D., D’Agostino, D., Volpe, S., Benfante, A., van Hooff, S. R., Iacobelli, V., Rossi, C., Iacobelli, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4642 · Cited by 38

Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models

Stegeman, H., Kaanders, J. H. A. M., van der Kogel, A. J., Iida, M., Wheeler, D. L., Span, P. N., & Bussink, J. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.02.001 · Cited by 38

Cetuximab in non-melanoma skin cancer

Wollina, U. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.681374 · Cited by 38

AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis

Tao, X., Lü, Y., Qiu, S., Wang, Y. N., Qin, J., & Fan, Z. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.012 · Cited by 38

Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells

You, K. S., Yi, Y. W., Cho, J., & Seong, Y. (2021) · Cancers · doi:10.3390/cancers13061205 · Cited by 37

Somatic variation and cancer: therapies lost in the mix

Biankin, A. V., & Hudson, T. J. (2011) · Human Genetics · doi:10.1007/s00439-011-1010-0 · Cited by 39

Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways

van der Meel, R., Oliveira, S., Altıntaş, I., Heukers, R., Pieters, E. H. E., Henegouwen, P. M. P. V. B. E., Storm, G., Hennink, W. E., Kok, R. J., & Schiffelers, R. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400212v · Cited by 38

miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC

Citron, F., Segatto, I., Musco, L., Pellarin, I., Vinciguerra, G. L. R., Franchin, G., Fanetti, G., Miccichè, F., Giacomarra, V., Lupato, V., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012872 · Cited by 37

Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells

Song, N., Liu, S., Zhang, J., Liu, J., Xu, L., Liu, Y., & Qu, X. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045838 · Cited by 38

Targeting HER (ERBB) signaling in head and neck cancer: An essential update

Zhang, J., Saba, N. F., Chen, G. Z., & Shin, D. M. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.07.001 · Cited by 37

Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs

Sahu, N., Stéphan, J.-P., Cruz, D. D., Merchant, M. A., Haley, B., Bourgon, R., Classon, M., & Settleman, J. (2016) · Nature Communications · doi:10.1038/ncomms12351 · Cited by 37

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling

Asbagh, L. A., Vázquez, I., Vecchione, L., Budínská, E., de Vriendt, V., Baietti, M. F., Steklov, M. Y., Jacobs, B., Hoe, N., Singh, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2458 · Cited by 36

miRNAs versus oncogenes: the power of social networking

Malumbres, M. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.2 · Cited by 36

Computer-aided design, synthesis, and biological evaluation of new indole-2-carboxamide derivatives as PI3Kα/EGFR inhibitors

Sweidan, K., Sabbah, D. A., Bardaweel, S. K., Dush, K. A., Sheikha, G. M. A., & Mubarak, M. S. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.011 · Cited by 36

Identification of New Peptide Ligands for Epidermal Growth Factor Receptor Using Phage Display and Computationally Modeling their Mode of Binding

Hamzeh‐Mivehroud, M., Mahmoudpour, A., & Dastmalchi, S. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01282.x · Cited by 35

EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells

Möller, Y., Siegemund, M., Beyes, S., Herr, R., Lecis, D., Delia, D., Kontermann, R. E., Brummer, T., Pfizenmaier, K., & Olayioye, M. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107165 · Cited by 35

Deregulation of the miR-16-KRAS axis promotes colorectal cancer

You, C., Liang, H., Sun, W., Li, J., Liu, Y., Fan, Q., Zhang, H., Yue, X., Li, J., Chen, X., et al. (2016) · Scientific Reports · doi:10.1038/srep37459 · Cited by 35

Concurrent Autophagy Inhibition Overcomes the Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Human Bladder Cancer Cells

Kang, M., Lee, K. H., Lee, H.-J., Jeong, C. W., Kwak, C. H., Kim, H. C., & Ku, J. H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020321 · Cited by 35

Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance

Saba, N. F., Chen, Z. G., Haigentz, M., Bossi, P., Rinaldo, A., Rodrigo, J. P., Mäkitie, A. A., Takes, R. P., Strojan, P., Vermorken, J. B., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0214 · Cited by 35

Advances in the design and synthesis of prazosin derivatives over the last ten years

Desiniotis, A., & Kyprianou, N. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.641534 · Cited by 35

Prevention of BMS‐777607‐induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics

Sharma, S., Yao, H., Zhou, Y.-Q., Zhou, J., Zhang, R., & Wang, M. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.014 · Cited by 35

Suppression of the Epidermal Growth Factor Receptor Inhibits Epithelial–Mesenchymal Transition in Human Pancreatic Cancer PANC-1 Cells

Chang, Z., Wei, J., Qin, C.-F., Hao, K., Tian, X., Xie, K., Xie, X., & Yang, Y.-M. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2036-4 · Cited by 34

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer

Mehra, R., Serebriiskii, I. G., Dunbrack, R. L., Robinson, M. K., Burtness, B. A., & Golemis, E. A. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.08.002 · Cited by 34

In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer

Tashiro, T., Okuyama, H., Endo, H., Kawada, K., Ashida, Y., Ohue, M., Sakai, Y., & Inoue, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174151 · Cited by 31

Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma

Shimizu, R., Ibaragi, S., Eguchi, T., Kuwajima, D., Kodama, S., Nishioka, T., Okui, T., Obata, K., Takabatake, K., Kawai, H., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4631 · Cited by 34

Investigational multitargeted kinase inhibitors in development for head and neck neoplasms

Šola, A. M., Johnson, D. E., & Grandis, J. R. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1581172 · Cited by 34

Transient receptor potential vanilloid 1 promotes EGFR ubiquitination and modulates EGFR/MAPK signalling in pancreatic cancer cells

Huang, J., Liu, J., & Qiu, L. (2020) · Cell Biochemistry and Function · doi:10.1002/cbf.3483 · Cited by 34

Ligand-Dependent Activation of EGFR in Follicular Dendritic Cells Sarcoma is Sustained by Local Production of Cognate Ligands

Vermi, W., Giurisato, E., Lonardi, S., Balzarini, P., Rossi, E., Medicina, D., Bosisio, D., Sozzani, S., Pellegrini, W., Doglioni, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1275 · Cited by 34

Advances in the proteomic discovery of novel therapeutic targets in cancer

Guo, S., Zou, J., & Wang, G. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s52216 · Cited by 34

Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium

Wang, P., Zhou, R., Zhou, R., Feng, S., Zhao, L., Li, W., Lin, J., Rajapakse, A., Lee, C., Furnari, F. B., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102976 · Cited by 34

Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage

Liccardi, G., Hartley, J. A., & Hochhauser, D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2695 · Cited by 33

BCR‐ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein

Buffa, P., Romano, C., Pandini, A., Massimino, M., Tirrò, E., Raimondo, F. D., Manzella, L., Fraternali, F., & Vigneri, P. G. (2013) · The FASEB Journal · doi:10.1096/fj.13-236992 · Cited by 34

Characterizing Glioblastoma Heterogeneity via Single-Cell Receptor Quantification

Chen, S., Le, T., Harley, B. A. C., & Imoukhuede, P. I. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00092 · Cited by 33

Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review

Wang, C., Zhang, Y., Chen, W., Wang, Y., & Xing, D. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188927 · Cited by 34

Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy

Yin, Y., Yuan, X., Gao, H., & Yang, Q. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118785 · Cited by 33

AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab

Li, X., Lü, Y., Lu, H., Luo, J., Hong, Y. K., & Fan, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3432 · Cited by 32

CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck

Meulenaere, A. D., Vermassen, T., Aspeslagh, S., Zwaenepoel, K., Deron, P. B., Duprez, F., Ferdinande, L., & Rottey, S. (2016) · Pathobiology · doi:10.1159/000446569 · Cited by 32

Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells

You, K. S., Yi, Y. W., Kwak, S., & Seong, Y. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4244 · Cited by 31

IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin

O’Flanagan, C. H., O’Shea, S., Lyons, A., Fogarty, F., McCabe, N., Kennedy, R. D., & O’Connor, R. (2016) · Oncotarget · doi:10.18632/oncotarget.10862 · Cited by 32

EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: A critical review

Raju, R. M., Jeffin Joy, A., Raghavendra, N. M., Justin, A., & Kumar, B. R. P. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101490 · Cited by 33

MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor

Chen, Y., Li, R. Q., Pan, M., Shi, Z., Yan, W., Liu, N., You, Y., Zhang, J., & Wang, X. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2463-3 · Cited by 31

Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab

Sun, C., Han, C., Jiang, Y., Han, N., Zhang, M., Li, G., & Qiao, Q. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188932 · Cited by 31

A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma

Zhang, M., Wang, B., Chong, Q.-Y., Pandey, V., Guo, Z., Chen, R.-M., Wang, L., Wang, Y., Ma, L., Kumar, A. P., et al. (2019) · Oncogenesis · doi:10.1038/s41389-019-0173-8 · Cited by 31

Radiosynthesis and biological evaluation of 18F-labeled 4-anilinoquinazoline derivative (18F-FEA-Erlotinib) as a potential EGFR PET agent

Huang, S., Han, Y., Chen, M., Hu, K., Qi, Y., Sun, P., Men, W., Wu, H., Li, G., Wang, Q., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.066 · Cited by 31

A deuterated analog of dasatinib disrupts cell cycle progression and displays anti‐non‐small cell lung cancer activity in vitro and in vivo

Ling, C., Chen, G., Chen, G., Zhang, Z., Cao, B., Han, K., Yin, J., Chu, A., Zhao, Y., & Mao, X. (2012) · International Journal of Cancer · doi:10.1002/ijc.27504 · Cited by 30

Gefitinib and pyrrolidine dithiocarbamate decrease viral replication and cytokine production in dengue virus infected human monocyte cultures

Durán, A., Valero, N. J., Mosquera, J., Fuenmayor, E., & Álvarez‐Mon, M. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.10.027 · Cited by 29

CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration

Geng, Y., Zheng, X., Zhang, D., Wei, S., Feng, J., Wang, W., Zhang, L., Wu, C., & Hu, W. (2024) · Biology Direct · doi:10.1186/s13062-024-00478-x · Cited by 29

Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro

Bourn, J. R., & Cekanova, M. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s158518 · Cited by 29

A novel derivative of picolinic acid induces endoplasmic reticulum stress-mediated apoptosis in human non-small cell lung cancer cells: synthesis, docking study, and anticancer activity

Abbas, A. H., Mahmood, A. A. R., Tahtamouni, L. H., Al-Mazaydeh, Z. A., Rammaha, M. S., Alsoubani, F. A., & Al-bayati, R. I. (2021) · Pharmacia · doi:10.3897/pharmacia.68.e70654 · Cited by 29

Constitutive Overexpression of the Oncogene Racl in the Airway of Recurrent Respiratory Papillomatosis Patients Is a Targetable Host-Susceptibility Factor

Lucs, A. V., Wu, R., Mullooly, V. M., Abramson, A. L., & Steinberg, B. M. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00447 · Cited by 29

Growth factor pathways in development and progression of hepatocellular carcinoma

Nalesnik, M. A. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s348 · Cited by 29

NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling

Lin, T., Wu, F.-J., Chang, C.-L., Li, Z., & Luo, C. (2016) · Oncotarget · doi:10.18632/oncotarget.7169 · Cited by 29

The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target

Gaffney, D. C., Soyer, H. P., & Simpson, F. (2013) · Australasian Journal of Dermatology · doi:10.1111/ajd.12025 · Cited by 28

The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors

Haines, E., Schlienger, S., & Claing, A. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1071737 · Cited by 28

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP)

CLICaP, O. B. O., Cardona, A. F., Arrieta, O. G., Laguado, M. I. Z., Rojas, L., Wills, B., Reguart, N., Karachaliou, N., Carranza, H., Vargas, C. A., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0497-2 · Cited by 29

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance

Tsubata, Y., Tanino, R., & Isobe, T. (2021) · Cells · doi:10.3390/cells10113192 · Cited by 31

Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma

Guo, T., Wu, C., Zhang, J., Yu, J., Li, G., Jiang, H., Zhang, X., Yu, R., & Liu, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01400-0 · Cited by 28

A Potential Peptide Therapeutic Derived from the Juxtamembrane Domain of the Epidermal Growth Factor Receptor

Boran, A. D. W., Seco, J., Jayaraman, V., Jayaraman, G., Zhao, S., Reddy, S., Chen, Y., & Iyengar, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049702 · Cited by 28

Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer

Madden, J. M., Mueller, K. L., Bollig-Fischer, A. B., Stemmer, P. M., Mattingly, R. R., & Boerner, J. L. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3102-8 · Cited by 26

Benzothiazole derivatives in the design of antitumor agents

Paoletti, N., & Supuran, C. T. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400259 · Cited by 27

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

Song, Y.-A., Ma, T., Zhang, X.-Y., Cheng, X.-S., Olajuyin, A. M., Sun, Z.-F., & Zhang, X.-J. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0836-8 · Cited by 27

Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC)

Makhov, P. B., Bychkov, I., Faezov, B., Deneka, A. Y., Kudinov, A. E., Nicolas, É., Brebion, R., Avril, E., Cai, K. Q., Kharin, L. V., et al. (2021) · Oncogenesis · doi:10.1038/s41389-021-00317-y · Cited by 28

Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma

Aboul‐Fettouh, N., Morse, D., Patel, J., & Migden, M. R. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.11s2a169s · Cited by 28

PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer

Luo, M., Huang, Z., Yang, X., Chen, Y., Jiang, J., Zhang, L., Zhou, L., Qin, S., Jin, P., Fu, S., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.12.011 · Cited by 28

MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells

Maharati, A., Zangouei, A. S., Khalili‐Tanha, G., & Moghbeli, M. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00840-4 · Cited by 28

Enhanced radiosensitivity of NSCLC cells by transducer of erbB2.1 (TOB1) through modulation of the MAPK/ERK pathway

Sun, K., Zhong, N., YANG, Y., Zhao, L., & Jiao, Y. (2013) · Oncology Reports · doi:10.3892/or.2013.2403 · Cited by 27

Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines

Stegeman, H., Kaanders, J. H. A. M., Verheijen, M. M., Peeters, W. J. M., Wheeler, D. L., Iida, M., Grenman, R. A., van der Kogel, A. J., Span, P. N., & Bussink, J. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-133 · Cited by 27

KITENIN functions as a fine regulator of ErbB4 expression level in colorectal cancer via protection of ErbB4 from E3‐ligase Nrdp1‐mediated degradation

Sun, E. G., Lee, K. H., Ko, Y., Choi, H. J., Yang, J., Lee, J. H., Chung, I. J., Paek, Y., Kim, H., Bae, J. A., et al. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22572 · Cited by 27

Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors

Liu, Z., Gao, Y., & Li, X. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1552139 · Cited by 27

MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis

Ko, Y., Bae, J. A., Kim, K. Y., Kim, S. J., Sun, E. G., Lee, K. H., Kim, N., Kang, H., Seo, Y.-W., Kim, H., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0954-8 · Cited by 27

Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma

Błaszczak, W., Barczak, W., Wegner, A., Golusiński, W., & Suchorska, W. M. (2017) · Medical Oncology · doi:10.1007/s12032-017-0918-1 · Cited by 26

Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol

Pearson, H. E., Iida, M., Orbuch, R. A., McDaniel, N. K., Nickel, K. P., Kimple, R. J., Arbiser, J. L., & Wheeler, D. L. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0384 · Cited by 26

PLGA Nanofiber/PDMS Microporous Composite Membrane-Sandwiched Microchip for Drug Testing

Li, W., Sun, X., Ji, B., Yang, X., Zhou, B., Lu, Z., & Gao, X. (2020) · Micromachines · doi:10.3390/mi11121054 · Cited by 26

A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer

Cao, W., Tang, Q., Zeng, J., Jin, X., Zu, L., & Xu, S. (2023) · Cancers · doi:10.3390/cancers15184561 · Cited by 28

Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia

Covell, D. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127433 · Cited by 24

Mechanisms of resistance to EGFR targeted therapies

Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67

Resistance mechanisms of tumour cells to EGFR inhibitors

Morgillo, F., Cantile, F., Fasano, M., Troiani, T., Martinelli, E., & Ciardiello, F. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0354-6 · Cited by 19

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Shi, K., Wang, G., Pei, J., Zhang, J., Wang, J., Ouyang, L., Wang, Y., & Li, W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01311-6 · Cited by 174

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy

Bianco, R., Troiani, T., Tortora, G., & Ciardiello, F. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00999 · Cited by 92